AEON Biopharma Inc (AMEX: AEON) has a higher price-to-earnings ratio of 0.00x compared to its average ratio, The 36-month beta value for AEON is at 0.64. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AEON is 9.43M, and currently, shorts hold a 12.49% of that float. The average trading volume for AEON on June 13, 2025 was 974.48K shares.
AEON) stock’s latest price update
The stock of AEON Biopharma Inc (AMEX: AEON) has decreased by -7.70 when compared to last closing price of 0.97.Despite this, the company has seen a gain of 22.21% in its stock price over the last five trading days. globenewswire.com reported 2025-05-23 that IRVINE, Calif., May 23, 2025 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today reported the grant in May of 102,880 restricted stock units (RSUs) of the Company’s common stock to newly hired non-executive employees of the company. The awards were approved by the Company’s Board of Directors under the AEON 2025 Inducement Incentive Plan, which a grant date and vesting commencement date of May 21, 2025.
AEON’s Market Performance
AEON Biopharma Inc (AEON) has seen a 22.21% rise in stock performance for the week, with a 77.60% gain in the past month and a 48.40% surge in the past quarter. The volatility ratio for the week is 7.03%, and the volatility levels for the past 30 days are at 6.51% for AEON. The simple moving average for the past 20 days is 37.22% for AEON’s stock, with a -96.87% simple moving average for the past 200 days.
Analysts’ Opinion of AEON
Many brokerage firms have already submitted their reports for AEON stocks, with H.C. Wainwright repeating the rating for AEON by listing it as a “Buy.” The predicted price for AEON in the upcoming period, according to H.C. Wainwright is $18 based on the research report published on August 18, 2023 of the previous year 2023.
AEON Trading at 68.23% from the 50-Day Moving Average
After a stumble in the market that brought AEON to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.67% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AEON starting from FISCHER JOST, who purchase 60,000 shares at the price of $0.49 back on May 21 ’25. After this action, FISCHER JOST now owns 266,785 shares of AEON Biopharma Inc, valued at $29,250 using the latest closing price.
FISCHER JOST, the Director of AEON Biopharma Inc, purchase 60,000 shares at $0.51 during a trade that took place back on May 20 ’25, which means that FISCHER JOST is holding 206,785 shares at $30,360 based on the most recent closing price.
Stock Fundamentals for AEON
The total capital return value is set at -6.63.
Based on AEON Biopharma Inc (AEON), the company’s capital structure generated -0.83 points at debt to capital in total, while cash flow to debt ratio is standing at -1.57.
Currently, EBITDA for the company is -27.73 million with net debt to EBITDA at -0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.43.
Conclusion
In conclusion, AEON Biopharma Inc (AEON) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
